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ABSTRACT 
BACKGROUND:  
Apopotosis is determined by the balance between the pro- and anti- apoptotic 
regulators in a cell. Bcl2 is the principal anti apoptotic regulator and bax is the principal 
pro- apoptotic factor that heterodimerizes with bcl2 and counteracts its function. The 
ratio of bcl2/bax is known to influence the prognosis of OSCC and it differs between the 
histological differentiation types of OSCC.  
AIM: 
Is to determine whether the ratio of bax and bcl2 expression have any significance 
with regard to clinicopathological parameters.   
OBJECTIVE OF THE STUDY 
 To evaluate the immunohistochemical expression of Bcl 2 and Bax genes in oral 
squamous cell carcinoma. 
MATERIALS AND METHODS: 
This is a prospective study involving 60 cases of histologically proven OSCC, 
collected between January 2012 and June 2012. The paraffin tissue blocks were prepared, 
cut and were stained immunohistochemically for bcl2 and bax. Their immunopositivity 
were then semiquantitatively analysed by giving scores to the percentage of cells stained. 
The bcl2/bax is then mathematically calculated. This ratio is then statistically analyzed 
for any significance in relation to age, sex, site, habit and clinical stage of the patient. 
RESULTS: 
 The bcl2/bax ratios for tongue cases were significantly higher than that of the 
other sites. Also within the tongue cases, the ratios for cases which had trauma as the 
etiological factor had significantly higher values. 
CONCLUSION: 
 OSCC of tongue is known to have poor prognosis than the other subsites of oral 
cavity as proved by other studies. Higher Bcl2/bax ratio than the rest of the subsites may 
be one of the reasons for this. Trauma causes a higher bcl2/bax ratio among the various 
etiologies causing tongue OSCC. 
 Key words: Apoptosis, Bcl2/bax ratio, Oral squamous cell carcinoma, Tongue 
OSCC.  
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INTRODUCTION 
Oral cancer is the eight commonest cancer worldwide, being more common in the 
south central Asian countries.
1
 In India, it is the most common fatal cancer type in men 
(22.9%) and third most common in women (9.8%). 
2
 
Oral carcinogenesis is the cumulative effect of events due to the combination of 
genetic predisposition and exposure to environmental carcinogens.
3
  In the case of oral 
squamous cell carcinoma (OSCC), the major environmental factor is tobacco.
1
 Chronic 
exposure to environmental factors cause genetic alterations like amplification of 
oncogenes and inactivation of tumour suppression genes in the epithelial cells.
4
 These 
alterations result in autonomous growth / increased proliferation.
4
  Such altered cells are 
normally eliminated by a process called apoptosis. However the evasion of this cell death 
results in further immortality.
4
  Or in other words, all neoplastic evolution requires two 
important steps, uncontrolled proliferation of cells and suppressed cell death of those 
cells. The cell death occurs by a programmed process called apoptosis.
5
  It is defined as, 
“A form of cell death designed to eliminate unwanted host cells through activation of a 
coordinated, internally programmed series of events effected by dedicated set of gene 
products.‟‟6 
Apoptosis is controlled by a family of regulatory proteins called „‟Bcl2 family of 
proteins”, encoded by the Bcl2 family of genes.6  This family includes both pro- and anti-
apoptotic proteins.
6
 The anti-apoptotic proteins are Bcl2 and Bcl-xL and the pro-
apoptotic proteins are Bax, Bak, Bad, Bik, and Bid.
6
 The relative concentrations of the 
pro- and anti-apoptotic members would decide the outcome of a cell challenged with an 
apoptotic stimulus.
7
  Bcl2 protein is the founding member of this family. It is encoded by 
2 
 
bcl2 gene located in the chromosome 18q21.
8 
Bcl-2 stands for B-cell lymphoma 2, as it 
was the second member of a range of proteins found associated with the mutations 
described in follicular lymphomas.
8
  
The literature shows a number of studies on apoptosis and its regulators in 
cancers
9-12
 including OSCC.
16-18
 Majority of these studies involve Bcl2 and Bax among 
the apoptosis regulators.
 
 In carcinogenesis, bcl2 and bax are considered as the principle 
anti- and pro- apoptotic regulators
13
 because bcl2 confers the pre- and malignant oral 
keratinocytes immunity from apoptosis.
14
 It also interferes with the cancer therapeutic 
methods by protecting the tumour cells from apoptosis induced by radiation, 
chemotherapy and growth factor deprivation.
9
 In contrast, bax plays the pivotal role in 
pro-apoptotic regulation by binding with and opposing the action of bcl2.
13,14
 Thus, the 
relative concentration of Bcl2 and Bax determines the fate of a cell‟s response to an 
apoptotic stimulus.
13 
 The purpose of this study is to evaluate the Bcl2/Bax in conjunction with the 
clinicopathologic parameters in OSCC to ascertain as to whether this ratio is influenced 
by the clinicopathologic parameters 
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AIM OF THE STUDY 
Is to determine whether the ratio of bax and bcl2 expression have any significance with 
regard to clinicopathological parameters.   
OBJECTIVE OF THE STUDY 
To evaluate the immunohistochemical expression of Bcl 2 and Bax genes in oral 
squamous cell carcinoma. 
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REVIEW OF LITERATURE 
A. STUDIES ON EPIDEMIOLOGY OF OSCC : DISTRIBUTION, AGE, SEX, 
SITE 
In the systematic review by Boyle et al in 1990
19
 the literature collected from 
various worldwide were included. This paper addresses the geographical variations in the 
incidence of OSCC.  Madras and poona were ranked as the second and third as the 
among the places with highest record of Oral cancer. France was ranked first. Males are 
affected more commonly than females. The top five cities with highest oral cancer cases 
in women were all from India and they were Bangalore, Madras, poona, Bombay and 
Magpur. They also explain the influence of etiological relation of tobacco, betal quid, 
smoking and snuff.  
 Sherin et al in 2008
20
, studied the changing trends in oral cancer in an 
instituitutional retrospective study of 206 cases in kerala, India; with an emphasis on the 
young patients (< 40years of age). The mean incidence during the study period was 7.5%. 
There was no sexual predilection in patients over 40 years but the younger age group 
showed a 3.5 higher incidence in males. The more commonest site in the older group was 
buccal mucosa, followed by tongue and gingiva. In younger age group tongue was the 
most common site, followed by buccal mucosa, gingiva and floor of the mouth. 
Moderately differentiated OSCCs formed the major histological grade. In young patients 
a large percentage of them ( 34%) showed no habit of tobacco, smoking or alcoholism.  
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 Zini et al in 2009
21
, analyzed the distribution and trends in oral cancer among 
Israeli population from 1970 to 2006 (6577 cases). Among these cases 57.2% were male 
and 42.8% were females. All the patients were above 55 years and it is suggested as 
another risk factor maker. Most prevalent oral cancer subtype was squamous cell 
carcinoma among men above the age of 55 years. Females had a higher incidence of SCC 
in lateral border of tongue, gums and buccal mucosa. The highest oral survival rate was 
for the lip, and the lowest was for the tongue and gums. 
 Sharma et al in 2010
22
, studied the recent trends in 80 OSCC patients in western 
Uttar Pradesh in India. Of them 68.7% were men and 31.2% were women with a male : 
female ratio of 2.2:1. The majority of the patients were in their 4
th
 and 5
th
 decade. 60% of 
them were using smokeless tobacco and 36.25% were smokers, using beedi or cigarette. 
The buccal mucosa was found to be the most common site. This may be because that 
majority of them are smokeless tobacco users, and buccal mucosa is the subset which is 
in more contact with it. The least common site was the palate.  
 Marocchio et al in 2010
23
 made a retrospective study on1564 OSCC cases, 
collected in an institution in sao paulo, over a period of 40 years. Males were more 
commonly affected, but the male: female ratio decreased gradually over the years. Most 
patients were in their 5
th
 and 6
th
 decade. The gingiva was the most affected site, but the 
frequency of lower lip involvement increased in the last time period. Regarding lesion 
size and duration of symptoms at the time of diagnosis, there was a significant difference 
between the first and last time periods. Smaller lesions were found and the time of lesion 
development was shorter in the last few years of the study. 
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 In a study by Byakodi et al in 2012
24
, in an institution in western Maharashtra, 
India, 112 OSCC cases were studied. 72.32% were male and 27.67% were female patient. 
The average age of the patients was 30–70 years.  25 to 30% consumed were either 
tobacco users or alcoholics. The most common site was lower alveolus followed by 
buccal mucosa. 
B. STUDIES ON HABITS ASSOCIATED WITH OSCC 
One of the earliest studies made about the risk factors in oral cancer among Indian 
population was done by Wahi et al in 1965
25
. This comprehensive study explains that 
variations in the incidence and common sites involved by oral cancer among different 
studies are probably because of the differences in the habitual etiological factors in 
different parts of the world. This involved 1916 patients from Agra, India. The risk 
factors for oral cancer included tobacco usage, smoking, alcoholism, malnutrition and 
poor oral hygiene and syphilis. This paper also explains the correlation between habit and 
the site involved. Out of 1916 patients, 821 of them had history of atleast one of the 
habits.  Tobacco was used either smokless form (tobacco chewing, betal quid + tobacco) 
or smoked tobacco (bidi, cigarette etc). 75.32% had habit of chewing tobacco in any 
form. They are in constant contact with the buccal mucosa or alveologingival sulcus. 
Hence the commonest site in this study was buccal mucosa. Majority of the smokers had 
cancer in anterior 2/3
rd
 of tongue followed by buccal mucosa. 
 Jussawala in 1970
26
 studied 2005 cases and found that the high risk sites for 
tobacco chewers and smokers were vice versa. The chewers had involvement in the 
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anterior part of oral cavity while the smokers had cancer involving the posterior region 
i.e. posterior 1/3 rd of tongue, soft palate, oropharynx and tonsils. 
 Jayant et al in 1977
27
 quantified the attributable risk of tobacco chewing in oral 
cancer. They found that tobacco usuage contributed to 70% of the oral cancers. 
 Sankaranarayanan et al in 1989
28
 studied 187 cases and found that daily 
frequency of tobacco chewing was the strongest predictor of risk in males, with a relative 
risk of 15.07 associated with chewing ten or more quids per day. The corresponding 
relative risk among females was 13.69. In males a relative risk of 3.20 was associated 
with smoking more than 20 bidis per day, and relative risks of 2.62 and 3.90 were 
associated with regular use of alcohol and snuff respectively. They concluded that there 
are four predictors of risk of oral cancer in the chewers/ smokers. They are tobacco daily 
frequency of tobacco usage, duration of smoking, and alcohol and snuff use (regular 
versus never). There were also significantly elevated risks associated with occasional 
indulgence in these four habits. 
 Znaor et al in 2003
29
 studied 1,563 oral, 636 pharyngeal and 566 esophageal 
male cancer patients and found that tobacco chewing is the strongest risk factor for oral 
cancer, and smoking for pharyngeal and esophageal cancer. Also there were significant 
decrease in risks for all 3 cancer sites in subjects who quit smoking. 
 Schmidt et al in 2004
30
 studied 67 OSCC cases and found that 67% of them were 
smokers. The most common sites of involvement were floor of the mouth and gingiva. 
This is in contradiction to that of  Jussawlla et al and Znaor et al. 
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 Madani et al in 2012
31
 gave a detailed description on the various types of 
tobacco products and their relative risks. This study involved 350 cases. The different 
indigenous forms of tobacco that is available today include chewable tobacco, paan / pan 
masala, gutkha, mishiri and beedi. Paan is natural crude areca nut wrapped in betal leaf, 
with lime, saffron, cinnamon and cloves. This product is now available in immediately 
consumable forms in sachet. With tobacco, it is gutkha ns without tobacco, it is called 
paan masala. Supari is a packet of natural crude areca nut without any additives. Mishiri 
is a chewable tobacco, like a tooth cleaner. The risk was highest for gutkha ( 7.3), 
followed by chewable tobacco (5.3 ), beedi ( 4.1), supari ( 4.0) and mishiri(2.2 ). 
 
C. STUDIES ON BCL2/BAX RATIO IN OTHER MALIGNANCIES 
 Brambilla et al in 1996
32
 studied the apoptosis, bax, bcl2 and p53 in 121 
neuroendocrine lung tumours including 16 typical carcinoids , 5 atypical carcinoids, 29 
large cell NE carcinomas and 71 small-cell lung carcinomas. Bcl2, bax and p53 were 
studied by immunohistochemistry. There was inverse correlation between bax and bcl2. 
Also the bcl2/bax ratio was inversed between the low grade and high grade tumours, 
there was bax predominance in low grade and bcl2 predominance in high grade tumours. 
Bc12 overexpression, Bax down-regulation, and Bcl / Bax ratio >1 correlated with lower 
apoptotic index in tumours with lower survival. 
In 2000, Mirjolet et al
33
 carried out a study in cell culture of head and neck 
carcinoma, breast carcinoma and pancreas cancer cell lines to check the sensitivity of 5-
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flourouracil, an anticancer drug. The sensitivity of the cells shows a positive correlation 
with bcl2 and bax ratio, irrespective of p53 gene status. 
 Scopa in 2001
9
 studied the bcl2/bax ratio in 35 rectal carcinoma patients after 
radiotherapy. Increased bcl2 decreased the prognosis and the opposite was true for bax. 
Thus the ratio was inversely proportional to the tumour prognosis. The bcl-2/bax ratio 
was greater in radiresistant group when compared with radiosensitive group and was 
correlated with poor responsiveness to radiotherapy. 
They concluded that the bcl2 / bax ratio can be used as an important molecular 
marker in predicting the tumour prognosis in rectal carcinoma cases.  
 In the work by Saxenna in 2004
12
, a positive correlation between the prognosis 
and low Bcl-2/Bax ratio similar to the rectal carcinoma was established. They have 
identified that both Bcl-2/Bax ratio and Mcl-1 are important cell-survival regulators in 
CLL with pathogenic and clinical significance. A large majority of patients with either 
low/Bcl-2 Bax ratio or low Mcl-1 or a combination of these findings are likely to exhibit 
some degree of response to conventional treatment. 
In a study by Matsumoto in 2004
11
, in a retrospective study of advanced bladder 
cancer cases which were treated by radiation combined with cisplatin therapy 
immunohistochemistry of bax and bcl2 was done. The bax / bcl2 ratio showed positive 
correlation with the response to treatment. 
In 2012 Kitada et al
34
 studied the expression of Bcl-2, Bcl-XL, Mcl-1, Bax, Bak, 
and BAD, BAG-1 and Caspase-3 in 58 peripheral blood samples of untreated CLL 
10 
 
patients by immunoblotting technique. Higher levels of Bcl-2 and a high Bcl-2: Bax ratio 
were correlated with high numbers of white blood cells. 
 
 
D. STUDIES ON BCL2 / BAX RATIO IN OSCC: 
 In 1996, Jordon et al
14
 studied the expression of bcl2 and bax in 30 OSCC cases 
and found that 18/ 30 cases (60%) were positive for bcl2 and 19 / 30 cases (63%) were 
positive for bax. In this study, the pattern of expression of bcl-2 and bax was inversely 
related to the grade of the tumor with intense immunostaining for bcl-2 and bax in poorly 
differentiated and well-differentiated SCC respectively. Bcl2 was expressed more in 
poorly differentiated tumours whereas bax was high among the well differentiated cases. 
Furthermore, there was strong bcl-2 overexpression in dysplastic areas adjacent to the 
invasive tumours. The authors believed, based on the expression patterns, that alteration 
in bcl-2 and bax is likely to play a role in the development of SCC, especially during the 
early stages of epithelial carcinogenesis. 
Staibano S et al in 1998
35
 investigated the prognostic role of Cyclin-D1, bcl-2, 
bcl-1, bax (protein X bcl-2-associated, PCNA and DNA-ploidy proteins in a series of 25 
SCC of the oral cavity. In 25 cases 20 cases were with a high/moderate degree of 
differentiation and five cases were with a low degree of differentiation. In this study they 
found that expression of Bcl-2 and bax absent in 76% and 60% respectively and present 
in 24% and 40 % respectively. Bcl-2 showed a weak expression in almost all the cases of 
SCC of this study, did not show a significant association with any of the other 
11 
 
parameters, such as cellular differentiation, age, sex, site, follow-up (length of time since 
surgery), disease-free interval and history of smoking, examined. The authors suggested 
that overexpression of  bax  seems  to  constitute an  additional  indicator  of  a  poor  
prognosis. 
Ito T et al 1999
36
 investigated the expression of apoptosis-related factors p53, 
Bax and Bcl-2 by an immunohisto-chemical approach using an apoptosis index 
employing an ApopTag kit and also the association between the immunohistochemical 
results and the clinicopathological data in 57 patients with oral and oropharyngeal SCC. 
There were six cases of stage I (11%), 11 cases of stage II (19%), 13 cases of stage III 
(23%), and 27 cases of stage IV (47%) SCC as classified by the general rules for clinical 
and pathological studies (TNM classification) on head and neck cancer. Of 57 cases 22 
(38.6%) were positive for Bax expression. The positive rate of Bax expression was higher 
at T1/T2 and clinical stage I/ II than at the more advanced stage (T3/T4 and stageIII/IV). 
Also, the positive rate of Bax expression was higher in the patients without than with 
lymph node metastasis. The disease-free survival of 5 years was higher in the Bax-
positive than the Bax-negative group, but the difference was not significant. There were 
no associations between Bcl-2 expression and tumor progression, metastasis, recurrence 
and death due to the disease. Moreover, Bcl-2 expression did not relate to prognosis. 
Apoptotic index (AI) in Bax-positive tumors was higher than in Bax-negative tumors, but 
not significant. AI was lower in Bcl-2-positive than Bcl-2-negative cases, but the 
difference was not significant. They suggested that the spontaneous apoptosis and 
apoptosis-related protein (p53, Bcl-2, Bax) are not important prognostic factors in 
12 
 
patients with oral and oropharyngeal SCC. However, the changes of apoptosis-related 
protein expression over primary therapy may contribute to the prediction of prognosis. 
In 1999, Loro et al
16
 assessed expression of bcl-2 and bax in conjunction with 
histological grading in oral SCC. They observed a cytoplasmic staining pattern for bcl-2 
within the thickness of normal epithelium with intense staining in the basal compartment, 
but negligible or loss of expression in the basal compartment of well-differentiated SCC. 
In contrast, bax expression was more intense in the central than in the basal part of the 
epithelium with higher proportion of bax positive cells in well- and moderately 
differentiated SCC compared to poorly differentiated SCC. They conclude that, in OSCC, 
compared with normal tissue, there is a decreased bcl-2 expression, a lowered bcl-2/bax 
ratio. The expression of bax correlates with histological tumor grading in OSCC.  
Homma et al 1999
37
 studied whether there is correlation between the treatment 
outcome and proliferative and apoptotic markers  i.e bcl2, bax, p53 and MIB-1 in 111 
H&N SCC patients who were concurrently treated with chemoradiation. They found 
significant correlation between bcl2 and local regional control and also between MIB-1 
and overall survival. This finding is controversial with the other studies, where the 
overexpression of bcl2 is correlated with poor prognosis. Also, no association was found 
between bax and prognosis. This study also assesses the clinical factors that can predict 
survival. And it was found that nodal involvement and histological differentiation are 
associated with poor treatment outcome. 
In 1999, Xie et al
18
 studied the prognostic values of apoptosis, bax, bcl2 and p53 
in OSCC of tongue. This study reveals that low apoptosis index (AI) scores and low bax 
13 
 
expression correlated significantly with poor prognosis, a low Bcl-2 expression was 
associated with a favorable clinical outcome. Patients with a high bcl-2/bax expression 
ratio had a significantly poorer prognosis than those with a low ratio. Bax expression, the 
bcl-2/bax expression ratio, and the TNM classifications were observed as significant 
independent prognostic variables.  However the bcl-2/bax expression ratio was concluded 
as the strongest independent prognostic parameter. 
In 2000, Chen et al
17
 evaluated the bcl2 and bax expression in OSCC and the bax 
mRNA and bcl2 mRNA by reverse transcriptase polymerase chain reaction. It was 
observed that the expression level of bcl-2 mRNA or bax mRNA was not consistent with 
their protein level in some cases. Higher expression of bcl-2 mRNA and stronger 
immunostaining of bcl-2 protein were found in oral OSCC than in the adjacent 
histologically normal OE. These findings were more prominent in poorly differentiated 
cases. No significant differences in bax mRNA and protein were observed between 
OSCC and the adjacent histologically normal OE. However, poorly differentiated 
carcinomas showed very weak immunostaining for bax. The ratio of bcl-2/bax mRNA 
was higher in OSCC than in the adjacent histologically normal OE, and higher ratios 
were seen in most of poorly differentiated OSCC. This study supplies indirect evidence 
of post-transcriptional control of bcl-2 and bax expression, and suggests that dysregulated 
expression of bcl-2 and bax may be related to the differentiation of OSCC. 
Loro et al in 2000
38
evaluated the expression of bcl2, bax, ki 67 and apoptosis in 
13 OSCC cases from sudan with toombak habit (snuff dipping) and 6 non-users from the 
Sudan and Norway by immunohistochemistry. Apoptosis was evaluated by the TUNEL 
method. They found a higher apoptotic rate and a higher bax expression in OSCC from 
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Norway compared with those from the Sudan (p < 0.05) irrespective of toombak use. No 
significant differences were detected in apoptosis, bax, bcl-2 and Ki-67 in OSCC from 
the Sudan in relation to toombak use. They concluded that in OSCC, apoptosis was 
associated with bax expression and was unaffected by p53 gene status or toombak use in 
OSCC from the Sudan. 
Teni et al in 2002
39
 assessed immunohistochemical expression of bcl2, bax and 
p53 in 63 oral squamous cell carcinoma patients among Indian population, to study the 
involvement of these apoptosis regulating proteins in OSCC in a population with habit of 
tobacco chewing. All of them had a history of tobacco chewing habit for a minimum of 
atleast 10 years. Of the 63 cases, 17 were well differentiated, 29 were moderately 
differentiated and 17 cases were poorly differentiated OSCC. They also included 11 
premalignant lesions including oral leukoplakia and oral submucous fibrosis cases in 
their study. They observed similar expression of both bcl2 and bax in the central cells of 
tumor islands and in the superficial epithelial layers of oral lesions. 56% of oral cancers 
and 16% of oral leukoplakia were positive for bcl2, bax was positive in 43% of oral 
cancers and 55% of oral lesions, p53 was positive in 54% of oral cancers and 43% of oral 
lesions. 30% of oral cancers demonstrated p53+bcl-2+ pattern and 14% of oral cancers 
were positive for all the 3 proteins. But none of the oral lesions showed overexpression of 
p53 and bcl-2 or all the three genes. Thus the bcl2, bax and p53 overexpression were 
concluded to have a critical role in the development of Indian OSCC by allowing 
apoptosis and also over expression in premalignant conditions suggest possible role of 
early carcinogenesis. 
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 The other findings in this study were, bcl2 expression significantly 
correlated with nodal status and therefore poor prognosis, and in contrast to all other 
studies of bcl2 and bax, the authors observed overexpression of both bcl2 and bax was 
more in moderate differentiated OSCC. 
In 2003, Sulkowska et al
40
 studied the correlation between bcl2 expression and 
clinicopathologic features in 129 OSCC cases. The study was conducted on 129 patients 
treated surgically for OSCC. Positive immunoreactivity for Bcl-2 was present as a coarse 
or finally granular cytoplasmatic staining, irregularly distributed around nuclei. Marked 
Bcl-2 expression was observed in the peripheral cells of squamous cell carcinoma 
focuses, diminishing toward their centers. Strong positive immunohistochemical staining 
was also observed in poorly differentiated squamous cell cancers and most cancer 
microfocuses at the tumor invasive margins.  
The statistically significant relationships were observed between oral squamous 
cell cancer Bcl-2 expression and higher tumor grading (p<0.005), higher tumor mitotic 
index (p<0.005), higher index of atypical mitoses (p<0.001) as well as microfocal pattern 
of tumor invasive margin (p<0.001). The results suggest that positive Bcl-2 expression 
may be a valuable factor supplementing the established unfavorable histopathological 
features of OSCC. 
In 2005, Assis et al
41
 made experimental trials in rats by exposing them to 
cigarette smoke and studied the changes in bcl2, bax, and PCNA between the 
experimental group and negative controls. the labeling index for bcl-2 and bax showed an 
increase 75 days after cigarette exposure. PCNA-labeling index did not show remarkable 
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changes between groups. An overexpression of bcl-2 was detected throughout all layers 
of the epithelium, whereas bax did not show significant differences. 
Loro et al in 2005
42
 in continuation to their work in 1999, they studied whether 
the underexpression of bcl2 in epithelial dysplasia and OSCC and that of bax in poorly 
differentiated OSCC is due to any mutations in bcl2 and bax, to correlate the expression 
pattern and to ascertain the mutational spectrum of these genes in epithelial dysplasia and 
oral SCC. This was done by immunohistochemical analysis of bcl2 and bax in 22 cases of 
oral epithelial dysplasia and 28 cases of OSCC and genomic extracton was done by in 
situ hybridisation from the paraffin blocks, and is then amplified. Tonsillar tissue is used 
as the positive control. Bcl2 was positive in the mantle zone and the bax was positive in 
the follicular centres of tonsillar tissue. They found that the expression of bax was widely 
noted in tumor cells of well-differentiated but not in poorly differentiated SCC compared 
to the low level of expression of bcl-2 in both histological grades of SCC. The authors 
concluded that loss of bcl-2 in basal cells of epithelial dysplasia and SCC as well as loss 
of bax in poorly differentiated SCC are not associated with mutations in the coding 
regions of these genes. 
De Vincent et al in 2006
43
 studied the expression pattern of bcl2 and bax in 35 
tongue cancr cases and also to correlate it with the clinicopathologic features and 
prognosis. Bax was detected in 37.1% (13 of 35 cases ). Bcl-2 was only 
immunoexpressed in 8.6% (3 of 35 cases). Both bcl2 and bax showed granular 
cytoplasmic positivity that was strong in the periphery of tumour islands which decreased 
towards centre. Carcinoma breast cells are used as control for bax and tonsil was used for 
bcl2, where it stained only the mantle zone. Bax correlated with histologic grading and 
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bcl2 with nodal status and poor prognosis. There was no correlation between bax or bcl2 
and age, sex, and T- size. It was concluded that bcl2 can be used as a predictor of 
patient‟s survival. 
Jane et al in 2006
44
 analyzed the expression of surviving, bcl2, bax and p53 in 38 
cases of OSCC and 17 leukoplakia cases among Indian population. Of the 38 OSCC 
cases, 13 were well differentiated, 14 were moderately differentiated and 11 were poorly 
differentiated. Breast carcinoma was used as positive control. The immunohistochemical 
analysis was based on the percentage cells stained. Bcl-2 staining cytoplasmic and in 
leukoplakia it was found in the keratin and prickle cell layer in weak to moderate 
intensities. 92.3% of well differentiated caese (12 out of 13 cases)  showed weak to 
moderate Bcl-2 expression. 57.14% of moderately differentiated cases showed moderate 
Bcl-2 expression and 100% of poorly differentiated cases showed strong Bcl-2 
expression. Bax was positive in the prickle cell layer and the basal layer of leukoplakia. 
84.62% of well differentiated OSCC, 90.91% of moderately differentiated OSCC and all 
of the poorly differentiated OSCC were positive for bax PDSCC. Thus both bax and bcl2 
increased with decrease in degree of histological differentiation of OSCC. Similar results 
were found for surviving and p53 protein.  
In 2007, Kummoona et al
45
 studied the expression pattern of bcl2 in 24 cases of 
oral cancer and correlated it to the clinicopathological features like patient‟s age, tumour 
size, lymph node metastasis. But none of the correlation was statistically significant. 
In 2008, Kato et al
46
 suggested that bax is a significant predictor of prognosis 
and is correlated with bcl2 and bax. Bax expression were significant and independent 
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variables. Bax expression was found to be the strongest independent prognostic 
parameter. Patients with negative Bcl-2 expression and positive Bax expression had a 
significantly better prognosis (P < 0.005). 
Zhang et al in 2009
47
, studied 110 OSCC cases and analysed the bcl2 / bax ratio 
and correlated with the parameters like histological grading, clinical staging and 
prognosis. Positive correlation was found only with prognosis. It was concluded that the 
treatment planning for the patients with bcl2 / bax >1, should be more intensive. 
Camicassa et al in 2009
47
 analyzed 53 OSCC cases clinically for TNM staging, 
histologically for lymphocytic infiltrate, pattern of invasion, perineural invasion, degree 
of differentiation and also immunohistochemically for bcl2, bax and bcl-x. These factors 
were correlated with prognosis. All of these factors were predictive of survival outcome. 
Tongue cases had low survival rate than other sites.  Digital image analysis was used to 
assess the immunohistochemical staining of bcl2, bax and bcl-x. Bcl2 and bcl-x were 
correlated with decreased survival and bax was associated with better survival.  
De souse et al in 2009
49
 made a comparative analysis of bcl2, bax, p53 and 
PCNA in OSCC and Lichen planus. In the study, of the 24 OSCC cases bax was positive 
in 66.7%  were positive for bax and 16.67% were positive for bcl2. There was correlation 
between bax and PCNA and between bcl2 and p53 only in lichen planus and no such 
correlation was observed in OSCC.  
Camillo et al in 2010
15
  carried out an extensive study involving multiple 
proteins of the bcl2 family that either inhibit (Bcl-2, Bcl-x, Bcl-xL, Bcl-2-related protein 
A1, BAG-1) or promote (Bak, Bax, Bim ⁄ Bod, Bim-Long, Bad, Bid, PUMA)apoptosis 
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and also to establish any  correlations between the expression of these proteins and 
clinicopathological features of OSCC like tumour site, clinical stage, nodal involvement, 
vascular invasion, perineural infiltration, histological grade and recurrence of OSCC. Bax 
was associated with absence of vascular invasion and with tumours occurring in the oral 
tongue. Bcl2 was not associated with any of the clinicopathological factors studied. 
Ranganathan et al in 2011
50
 attempted to compare the proliferative (Ki67) and 
apoptotic markers (bcl2, bax and p53) between 50 cases of OSMF and 10 cases of OSCC. 
10 normal oral epithelial tissue samples. The bcl2 was positive only in one case of OSMF 
and one case of OSCC and in none of the normal oral epithelium. Bax showed 
cytoplasmic positivity in 8 normal oral epithelium, 38 OSMF and all cases OSCC. The 
bax staining was seen in the basal and suprabasal layers both in the normal samples and 
OSCC cases. 
Zhao et in 2011
51
 studied the relationship between the apoptosis and the bcl2, bax 
proteins in 15 cases of maxillofacial squamous cell carcinoma,  after exposing them to 
thermochemotherapy (microwave induced hyperthermia + bleomycin injection). Out of 
these 15 cases, 9 patients had lip cancer and 6 of them had facial skin cancer. 
Histologically, tumors were graded as poorly differentiated (3 cases), moderately 
differentiated (8 cases), and well differentiated (4 cases). Bcl2 and bax expression was 
studied by immunohistochemistry before and after thermochemotherapy. The results 
showed that bcl2 was downregulated and apoptosis, bax were upregulated after the 
procedure. The authors conclude stating that the therapeutic procedures for SCC act by 
upregulating the pro- apoptotic proteins and by down regulating bcl2.  
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Jham et in 2012
52
 studied the expression of MK (midkine), Ki-67, PCNA, p53, 
bcl-2, Bax, and CD31 in 28 OSCC cases.  The expression of bcl-2 was increased in MK-
positive tumors. This was in contrast to the expression bax, which was unaltered in  MK-
positive cells. Therefore, the authors conclude saying that the MK participates in 
tumorigenesis via increased expression of anti-apoptic proteins, leading to a decrease in 
cell death. 
Bose et al in 2012
53
 studied the association between apoptosis-regulating proteins 
(bcl2, bax and bcl-Xl) and clinical outcomes in OSCC using the quantitative fluorescence 
immunohistochemistry (IHC) based AQUAnalysis technique. This was done both in 
normal oral epithelium and in 69 OSCC cases. They observed a nuclear positivity of bax 
in the basal layers of normal epithelium and cytoplasmic overexpression in the OSCC 
samples.  
E. STUDIES ON IHC ANALYSIS OF BCL2 & BAX 
In Nakawaga et al in 1994
54
, the positive cells were scored in several randomly 
selected fields at X400 magnification. The percentage of positive cells was classified as 
follows: (+++: strongly positive) more than 50% of the total cells were stained against 
bcl-2 antibody in the cytoplasm; (++: moderately positive) 25-50% of the total cells were 
stained; (+: weakly positive) 5-25% of the total cells were stained; (-: negative) less than 
5% of the total cells were stained. 
Xie et al in 1999
18
, studied the immunopositivity of bcl2 and bax by adding the % of 
Bcl2 and Bax positive cells and adding it with the  intensity of staining.  The score for % 
of positive cells are: 1 to 30 % of positive cells – 1 31 to 70% of positive cells – 2 and 71 
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to 100% of positive cells – 3. Intensity of staining is scored as Strongly positice- 3, 
moderately positive – 2, weakly positive – 1. 
 
 
 
MATERIALS AND METHODS: 
SOURCE: 
Out-patient department,  
Department of Oral Pathology,  
Tamil Nadu Government Dental College & Hospital,  
Chennai- 600 003. 
SUBJECTS 
Histologically confirmed oral squamous cell carcinoma patients, irrespective of age and 
gender. 
SAMPLE SIZE 
All cases of oral squamous cell carcinoma patients who will be reporting to the 
department to receive their biopsy report (January 2012 to June 2012), will be 
prospectively included in this study. The expected sample size is 60. 
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INCLUSION CRITERIA 
1. Patients with histologically proven cases of oral squamous cell carcinoma who 
had signed the informed consent. 
2. OSCC cases of any stage of TNM classification.  
3. OSCC Cases of any histological grading. 
4. Patients with or without habit of smoking or tobacco chewing of any form. 
5. Patients with or without history of trauma. 
EXCLUSION CRITERIA 
1. Cases without unequivocal evidence of squamous cell carcinoma. 
2. Patients with more than one etiological factor. 
METHODOLOGY: 
 History of Tobacco chewing/ smoking/ trauma is recorded from the patient. 
 Patient is clinically examined and TNM staging of the tumour (by Pierre Denoix 
between 1943 and 1952) is recorded. 
 H & E sections (4µ thickness), made from paraffin blocks of the patient are 
examined and histological grading is done.  
 Immunohistochemical analysis of Bcl2, Bax are made in the paraffin sections (4µ 
thickness) for all cases, using the avidin-biotin peroxidase technique (by Hsu et al 
1981)
[6]
, with relevant positive and negative controls.  
 IMMUNOHISTOCHEMICAL PROCEDURE: 
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 4 micron thickness are made on amino propyl triethoxy silane (APES) 
slides. 
 The slides are deparafinized and heat fixed at 55 to 60 degrees centigrade 
overnight. 
 They are then treated with following washes 
1. Xylene: 2 x 3 minutes  
2. Xylene 1:1 with 100% ethanol: 3 minutes  
3. 100% ethanol: 2 x 3 minutes  
4. 95% ethanol: 3 minutes  
5. 70 % ethanol: 3 minutes  
6. 50 % ethanol: 3 minutes  
7. Running cold tap water to rinse 
 Antigen retrieval: Place the slide rack in Tris-EDTA buffer (9 pH) in a 
pressure cooker for about ten minutes (3 whistles) 
 The pressure cooker is then bench cooled for 20 minutes. 
 Slide rack is then taken out, and washed in running water and distilled water. 
 Slides are then placed in a humidified chamber. 
 Sections are then treated with 3% hydrogen peroxide for 20 minutes to block 
endogenous peroxidase activity. 
 Slides are washed in tris buffer (pH 7.6) 
 Sections are then treated with power block 
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 Treat with primary antibody (anti bax / anti bcl2) for 1 hour. 
 Tris buffer wash 
 Treat with secondary antibody for 30 minutes. 
 Tris buffer wash. 
 Stain with DAB (3-diaminobenzidine) chromogen. 
 Wash with distilled water. 
 Counterstain with hematoxylin. 
 SCORING OF BCL2 AND BAX EXPRESSION: 
The % of Bcl2 and Bax positive cells will be calculated semiquantitatively, 
irrespective of the intensity of staining by a applying the modifiesd semiquantitative 
method followed by Xie et al in 1999,
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1 to 30 % of positive cells – 1 
31 to 70% of positive cells – 2 
71 to 100% of positive cells – 3 
Scoring is done in atleast 4 or 5 high power fields per slide and  the average score is 
noted for that slide. The ratio is then calculated. 
 CLINICOPATHOLOGIC EVALUATION: 
The Bcl2/Bax ratio will be interpreted in the context of the following clinicopathological 
parameters: 
1. Age 
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2. Sex 
3. Site 
4. Presence or absence of Trauma / Smoking / Tobacco history 
5. TNM Stage 
6. Histological grade. 
STATISTICAL ANALYSIS: 
 The collected data was analysed with SPSS 16.0 version. To describe about the 
data descriptive statistics mean, S.D were used. To find the significance difference 
between the bivariate samples independent t-test test was used. For the multivariate 
analysis the analysis of variance (ANOVA) with Post-hoc test Tukey's HSD was used to 
find the significance difference between the inter group comparison . In all the above 
statistical tools the probability value P=.05 is considered as significant level.  
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Fig 1. Primary anti bax & anti bcl2 antibodies                  Fig 2. Secondary poly-hrp antibody kit                       
 
 
                                  
Fig 3. Light microscope used for analysis of  
bcl2 & bax immunostained slides 
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GENERAL DISTRIBUTION 
The gender ratio was 1.87 with the distribution showing a male predominance 
with 65% males cases (39/60 cases) and 35% female cases (21/60 cases). The age of the 
patients ranged from 26 to 86 years. Patients were categorized into three age groups for 
comparison purpose. They are 25 to 45 years, 46 to 65 years and 66 to 86 years. 55% of 
the patients belonged to the 46-65 years age group, 30% belonged to 25-56 years age 
group and 15% of the patients belonged to 65-86 years age group. The buccal mucosa 
was the most common site and formed 30% (18/60 cases), this was followed by alveolar 
mucosa (26.66% or 16/60 cases), retro molar zone (21.67% or 13/60 cases) and tongue 
(21.67% or 13/60 cases). 
All of the patients had a history of atleast one habit, and the gutkha / maawa 
chewing habit was the most common habit among the cases (35% i.e 21/60 cases), 
followed by betal quid chewers (30% or 18/60 cases), smokers (16.67% or 10/60 cases), 
snuff users (10% or 6/60 cases) and 8.3% of patients had history of trauma (5/60 cases). 
All of them who had history of trauma belonged to the tongue OSCC cases.  
Among the 60 cases studied, 57 cases (95%) were of well differentiated OSCC, 
and 7 cases are of (11.67%) were of moderately differentiated type. Not a single case of 
poorly differentiated OSCC was recorded during the period. 
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Fig.4: Gender distribution 
 
 
 
Fig.5: Distribution of habits 
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Fig.6: Distribution of diseases stage 
 
 
Fig.7: Age distribution 
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IMMUNOHISTOCHEMISTRY RESULTS 
CONTROL TISSUE: 
 BCL2: 
 Diffuse, strong, cytoplasmic positivity in the mantle zone and 
interfollicular area of tonsil tissue. (Fig.8) 
 BAX: 
Diffuse, strong, cytoplasmic positivity in the tumour epithelial islands of 
carcinoma breast. (Fig.9) 
NORMAL EPITHELIUM: 
 BCL2: 
Moderate to strongly cytoplasmic positivity seen in the basal layers. 
(Fig.10) 
 BAX: 
Moderate to strong cytoplasmic positivity seen in basal and suprabasal 
layers of the epithelium. (Fig.11) 
OSCC SAMPLES: 
 BCL2: 
Diffuse, weak to moderate cytoplasmic positivity seen in the islands and 
dysplastic epithelium. Majority of the samples were weakly 
positive.(Fig.14, 15, 16)  
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 BAX: 
Diffuse, moderate to strong cytoplasmic positivity, sometimes 
strong only in the peripheral cells of tumour islands and sometimes 
stronger throughout the entire thickness of tumour island was seen. (Fig 
12, 13, 17) 
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BCL2 & BAX IN CONTROL TISSUES 
        
Fig.8: Bcl2 staining in control tissue – Tonsil (mantle zone & interfollicular area)  
                  
           Fig.9: Bax staining in the control tissue – Breast carcinoma 
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BCL2 & BAX IN NORMAL EPITHELIUM 
                    
                Fig.10: BCL2 In normal oral epithelium – Strong in basal cells. 
                           
               Fig.11: Bax in normal epithelium – stronger throughout the thickness. 
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BAX IN TEST SLIDES 
                     
Fig.12: Strong bax positivity in well differentiated tumour in 40X  
(score 3/HPF) 
                 
Fig.13: Bax in low power view (few areas can be given a score of 2, others 3/HPF) 
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BCL2 IN TEST SLIDES 
   
Fig.14: Strong immunopositivity of bcl2 in Moderately differentiated tumous 
 (Score 3/HPF) 
 
Fig.15: Bcl2 in showing intermixed positive and negative cells (Score 2/HPF) 
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COMPARISON OF BAX & BCL2 IN A CASE 
 
Fig.16: Weakly positive bcl2 (score 1/HPF) 
  
Fig.17: Strongly positive bax in the same focus (score 3/HPF) 
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ANALYSIS OF BCL2/BAX RATIO (Fig. 18) 
 
The difference between the bcl2/bax was not significant between the OSCC cases 
that involved buccal mucosa, alveolar mucosa and retromolar zone. But the bcl2/bax was 
significantly different between the tongue cases and the cases that involved other sites. 
The subsites were then classified according to the age groups, sex, habit and clinical 
stage. The bcl2/bax values were tabulated accordingly. 
 
 
Fig.18: Comparison between the bcl2/bax ratio between sites 
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ANALYSIS OF BCL2/BAX AMONG THE BUCCAL MUCOSA CASES  
(Table 1a,b,c) 
Among the buccal mucosa cases, 62.50% were female (10/16 cases) and 37.50% 
were male (6/16 cases) with a sex ratio of 0.6. This contradicted with the overall sex 
ratio. The age distribution was however similar to that of the overall picture. The majority 
of the cases belonged to the 46-65 years group (56.25% or 9/16 cases), with 37.5% in 25-
45 years age group (6/16 cases) and 6.25% in the 66-86% age group (1/16 cases). Equal 
number of cases had betal quid and maawa/gutkha chewing habits (37.5% or 6/16 cases 
each). This was followed by snuff dipping habit (18.75% or 3/16 cases) and only one 
case had habit of smoking (6.25%). 50% of cases belonged to the stage IV of TNM 
classification. 25 % in the stage III, 12.5% each in stage I and II.  None of these factors 
significantly affected the bcl2/bax ratio. 
 
Table 1a: Comparison Of Bcl2/Bax Between The Age Ranges  
Age Ranges In Years Mean Std. Deviation P- value Sig. 
25 TO 45 0.4283 0.11839 
0.510 NS  46 TO 65 0.4822 0.17570 
66 TO 95 0.3000 . 
 
 
 
 
39 
 
Table 1b: Comparison Of Bcl2/Bax Between The Habits  
Habit  Mean Std. Deviation P-VALUE Sig. 
B.Quid .3767 .09832 
.309 NS 
Smoking .5000 . 
Gutkha  /maawa .4500 .14339 
Snuff .5833 .23714 
 
Table 1c: Comparison Of Bcl2/Bax Between The TNM Stages  
TNM Stage  Mean Std. Deviation P-VALUE Sig. 
Stage I .4750 .10607 
.339 NS 
Stage II .2600 .05657 
Stage III .4800 .13266 
Stage IV .4775 .16960 
 
ANALYSIS OF BCL2/BAX AMONG THE ALVEOLAR MUCOSA CASES  
(Table 2a,b,c) 
Among the alveolar mucosa cases, 53.30% were male (8/15 cases) and 46.70% 
were female (7/15 cases) with a sex ratio of 0.87. This contradicted with the overall sex 
ratio. The majority of the cases belonged to the 46-65 years group (73.30% or 11/15 
cases) and the remaining 26.7% is in 66-95 years age group (4/15 cases). In this group 
most of the patients had betal quid habit (53.30% or 8/15 cases) followed by smoking and 
snuff dipping habit (33.3% or 5/15 cases and 13.40% or 2/15 cases respectively). 73.30% 
of cases belonged to the stage IV of TNM classification, 20% in the stage III and 6.70% 
in stage I.  None of these factors significantly affected the bcl2/bax ratio. 
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Table 2a: Comparison Of Bcl2/Bax Between The Age Ranges 
Age Ranges In Years Mean 
Std. 
Deviation 
P-VALUE Sig. 
AGE 46 TO 65 .4591 .15469 
.403 NS 
AGE 66 TO 95 .5375 .15756 
 
Table 2b: Comparison Of Bcl2/Bax Between The Habits 
Habit  Mean 
Std. 
Deviation 
P-VALUE Sig. 
 Betel quid .4800 .18639 
.804 NS Smoking .5060 .12482 
Snuff .4150 .12021 
 
Table 2c: Comparison Of Bcl2/Bax Between The TNM Stages 
TNM Stage  Mean 
Std. 
Deviation 
P-VALUE Sig. 
Stage I .6600 . 
.446 NS Stage III .5100 .14526 
Stage IV .4555 .15744 
            
ANALYSIS OF BCL2/BAX AMONG THE RETROMOLAR ZONE CASES 
 (Table 3a,b,c) 
Among the retromolar cases, 91.90% were male (10/11 cases) and 9.10% were 
female (1/11 cases) with a sex ratio of 0.1. This contradicted with the overall sex ratio. 
The majority of the cases belonged to the 46-65 years group (54.50% or 6/11 cases) and 
45.5% is in 25-45 years age group (5/11 cases). Maximum number of patients had gutka 
habit (45.5% or 5/11 cases) followed by betal quid habit (27.20% or 3/11 cases) smoking 
(18.20% or 2/11 cases) and snuff dipping habit (9.10% or 1/11 cases). 72.70% of cases 
belonged to the stage IV of TNM classification, 18.20% in the stage III and 9.10% in 
stage I.  None of these factors significantly affected the bcl2/bax ratio. 
41 
 
Table 3a: Comparison Of Bcl2/Bax Between The Age Ranges 
Age Ranges In Years Mean 
Std. 
Deviation 
P-VALUE Sig. 
Age 25 to 45 .5980 .25322 
.957 NS 
Age 46 to 65 .6050 .16294 
 
Table 3b: Comparison Of Bcl2/Bax Between The Habits 
Habit  Mean 
Std. 
Deviation 
P-VALUE Sig. 
Betel quid .7667 .25166 
.291 NS 
Smoking .6650 .23335 
Gutkha/ maawa .4980 .11670 
Snuff .5000 . 
 
Table 3c: Comparison Of Bcl2/Bax Between The TNM Stages 
TNM Stage  Mean 
Std. 
Deviation 
P-VALUE Sig. 
Stage I .3300 . 
.247 NS Stage III .7450 .12021 
Stage IV .6000 .19272 
 
ANALYSIS OF BCL2/BAX AMONG THE TONGUE CASES  
(Table 4a,b,c) 
Among the tongue cases, 91.90% were male (10/11 cases) and 9.10% were 
female (1/11 cases) with a sex ratio of 0.1. This contradicted with the overall sex ratio. 
The majority of the cases belonged to the 25-45 years group (45.60% or56/11 cases) 
followed by 27.20% is in both 45-65 years and 66-95 years age group (3/11 cases in each 
group). 45.50% patients had gutka/maawa habit (45.5% or 5/11 cases) and 45.50% had 
trauma followed by smoking habit (9% or 1/11 cases). 72.70% of cases belonged to the 
stage III of TNM classification, followed by 18.20% in the stage II and 9.10% in stage I. 
In this site habits or the risk factors affects the bcl2/bax expression as it shows the 
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significant difference in bcl2/bax ratio between trauma group and smoking and gutkha 
group(Fig.6). 
Table 4a: Comparison Of Bcl2/Bax Between The Age Ranges 
Age ranges Mean 
Std. 
Deviation 
P-VALUE Sig. 
Age 25 to 45 1.0140 .40605 
.144 NS Age 46 to 65 .5533 .06110 
Age 66 to 95 1.0433 .23798 
 
 
Table 4b: Comparison Of Bcl2/Bax Between The Habits 
Habit  Mean 
Std. 
Deviation 
P-VALUE Sig. 
Smoking .8300 . 
0.000* S Gutkha/ maawa .5800 .08000 
Trauma 1.2260 .21995 
 
              
Table 4c: Comparison Of Bcl2/Bax Between The TNM Stages 
TNM Stage  Mean Std. Deviation P-VALUE Sig. 
Stage I 1.0000 . 
.954 NS Stage II .9200 .53740 
Stage III .8775 .37105 
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Fig.19: Comparison of bcl2/bax ratio  
between the habits (risk factors) of tongue OSCC 
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DISCUSSION: 
 Oral cancer is currently the sixth most common type of cancer.
21
 The greatest 
number of OSCC cases is from the south central asian countries which includes India
1
. In 
India, it is currently the most common cancer type in men (22.9%) and third most 
common cancer type in women (9.8%)
 2
. 
It affects the age group between 50 to 55 years and it is more common among 
males .
25
 The common site varies among different studies conducted in different 
population.
19-31
 In India, the commonest site is buccal mucosa as the most common habit 
observed among Indian population is betal quid chewing.
25
 It is a type of tumour that is 
greatly influenced by habit and lifestyle of people, that varies in different parts of the the 
world. The habit in turn causes differences in the common site affected, and prognosis of 
OSCC cases in the various epidemiological studies conducted in different regions. The 
habits that are associated with OSCC include betal quid chewing, maawa/gutkha 
chewing, snuff dipping, smoking and alcoholism.
25-31 
  Oral cancer is not only the common cancer in India but is also the type of the 
tumour that causes the highest number of deaths due to cancer.
2
 The prognosis of OSCC 
depends on various patient factors (Habit, oral hygiene, immune status etc), tumour 
related factors (anatomic site, tumour size & depth, nodal metastasis, histological 
differentiation) and also molecular factors (proliferative and apoptotic factors). 
54
 
 This study concentrates on the immunohistochemical apoptotic proteins namely, 
bcl2 and bax proteins. The bcl2 is the principal antiapoptotic protein and bax is the 
principal proapoptotic protein that heterodimerizes with bcl2. 
25
The ratio between the bax 
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and bcl2 determines the fate of cell and acts as the threshold step for apopotosis.
55
 This 
ratio of bcl2/bax is the strongest prognostic marker for OSCC
18
 and varies with 
histological degree of differentiation.
16 
 In this prospective study, bcl2/bax is assessed in relation to various 
clinicopathological factors like age, sex, site of lesion, habit of the patients. During this 
period the number of cases involving the floor of the mouth (1 case), palate (2 cases) and 
lips (2 cases) were minimal with no comparable amount of data. Therefore they were 
eliminated from the study. Among the remaining cases, the first 60 were included in the 
study.  
 Majority of the patients were between 45 to 65 years of age (55%). 65% of them 
were males and 35% were females. Both these observations are in unison with many 
other studies that were performed earlier.
19-31 
 The buccal mucosa was the most common site and formed 30% (18/60 cases), this 
was followed by alveolar mucosa (26.67% or 16/60 cases), retro molar zone (21.67% or 
13/60 cases) and tongue (21.67% or 13/60 cases). This observation coincided with the 
other sherin et al, Sharma et al etc that was conducted in different parts of India
20, 22, 25, 26
. 
Although it however differed from other studies conducted elsewhere.
30 
All of the patients had a history of atleast one habit, and the gutkha / maawa 
chewing habit was the most common habit among the cases (35% i.e 21/60 cases), 
followed by betal quid chewers (30% or 18/60 cases), smokers (16.67% or 10/60 cases), 
snuff users (10% or 6/60 cases) and 8.3% of patients had history of trauma (5/60 cases). 
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All of them who had history of trauma belonged to the tongue OSCC cases. This was also 
similar to Sharma et al, Sherin et al.
20, 22 
Among the 60 cases studied, 57 cases (95%) were of well differentiated OSCC, 
and 7 cases are of (11.67%) were of moderately differentiated type. Not a single case of 
poorly differentiated OSCC was recorded during the period. Since the histological 
differentiation is known to influence the bcl2/bax ratio
16
, those 7 moderately 
differentiated cases were separated from the rest of the well differentiated cases to avoid 
the influence of the histological differentiation as a confounding factor. 
The difference between the bcl2/bax was not significant between the OSCC cases 
that involved buccal mucosa, alveolar mucosa and retromolar zone. But the bcl2/bax was 
significantly different between the tongue cases and the cases that involved other sites. 
The subsites were then classified according to the age groups, sex, habit and clinical 
stage. The bcl2/bax values were tabulated accordingly.  
Among the buccal mucosa cases, 62.50% were female (10/16 cases) and 37.50% 
were male (6/16 cases) with a sex ratio of 0.6. This contradicted with the overall sex 
ratio. The age distribution was however similar to that of the overall picture. The majority 
of the cases belonged to the 46-65 years group (56.25% or 9/16 cases), with 37.5% in 25-
45 years age group (6/16 cases) and 6.25% in the 66-86% age group (1/16 cases). Equal 
number of cases had betal quid and maawa/gutkha chewing habits (37.5% or 6/16 cases 
each). This was followed by snuff dipping habit (18.75% or 3/16 cases) and only one 
case had habit of smoking (6.25%). 50% of cases belonged to the stage IV of TNM 
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classification. 25 % in the stage III, 12.5% each in stage I and II.  None of these factors 
significantly affected the bcl2/bax ratio. 
Among the alveolar mucosa cases, 53.30% were male (8/15 cases) and 46.70% 
were female (7/15 cases) with a sex ratio of 0.87. This contradicted with the overall sex 
ratio. The majority of the cases belonged to the 46-65 years group (73.30% or 11/15 
cases) and the remaining 26.7% is in 66-95 years age group (4/15 cases). In this group 
most of the patients had betal quid habit (53.30% or 8/15 cases) followed by smoking and 
snuff dipping habit (33.3% or 5/15 cases and 13.40% or 2/15 cases respectively). 73.30% 
of cases belonged to the stage IV of TNM classification, 20% in the stage III and 6.70% 
in stage I.  None of these factors significantly affected the bcl2/bax ratio. 
In the retromolar zone cases 91.90% were male (10/11 cases) and 9.10% were 
female (1/11 cases) with a sex ratio of 0.1. This contradicted with the overall sex ratio. 
The majority of the cases belonged to the 46-65 years group (54.50% or 6/11 cases) and 
45.5% is in 25-45 years age group (5/11 cases). Maximum number of patients had gutka 
habit (45.5% or 5/11 cases) followed by betal quid habit (27.20% or 3/11 cases) smoking 
(18.20% or 2/11 cases) and snuff dipping habit (9.10% or 1/11 cases). 72.70% of cases 
belonged to the stage IV of TNM classification, 18.20% in the stage III and 9.10% in 
stage I.  None of these factors significantly affected the bcl2/bax ratio. 
In tongue cases, 91.90% were male (10/11 cases) and 9.10% were female (1/11 
cases) with a sex ratio of 0.1. This contradicted with the overall sex ratio. The majority of 
the cases belonged to the 25-45 years group (45.60% or56/11 cases) followed by 27.20% 
is in both 45-65 years and 66-95 years age group (3/11 cases in each group). 45.50% 
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patients had gutka/maawa habit (45.5% or 5/11 cases) and 45.50% had trauma followed 
by smoking habit (9% or 1/11 cases). 72.70% of cases belonged to the stage III of TNM 
classification, followed by 18.20% in the stage II and 9.10% in stage I. In this site habits 
or the risk factors affects the bcl2/bax expression as it shows the significant difference in 
bcl2/bax ratio between trauma group and smoking and gutkha group (Fig.6). 
The statistical significant higher bcl2/bax in the tongue cases infers that the 
prognoses in these cases are lower than the cases from other subsites. Tongue OSCC 
cases are known to have poor prognosis than the other OSCC.
56
 Various factors have 
been put forth to explain its poor prognosis.
56
 The bcl2/bax might well be a factor that 
contributes to this fact. Also among the various etiological factors that cause tongue 
OSCC, trauma forms the most important and common cause of OSCC. The bcl2/bax for 
the cases due to trauma has the highest value among all other factors. It is not known 
whether trauma causes a high bcl2/bax ratio or whether an increased bcl2/bax has 
prompted the development of OSCC when exposed to trauma. However there is a strong 
correlation between the ratio and trauma. Further studies are required to know more about 
this.   
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SUMMARY: 
 The ratio of bcl2 and bax is an immunohistochemical factor that was already 
proved to correlate with the histological differentiation and prognosis of OSCC. This 
study was designed to understand why this ratio is different among different OSCC 
patients. This was done by assessing the influence of clinicopathological factors like age, 
sex, site and habit on this ratio and also whether there is difference in the ratio between 
the different TNM stages. 
 The prospective was conducted on a sample of first 60 OSCC cases, collected 
between the month of January 2012 to May 2012, in the Department of Oral and 
maxillofacial pathology, Tamilnadu government dental college & hospital, Chennai. 
 During this period the number of cases involving the floor of the mouth (1 case), 
palate(2 cases) and lips (2 cases) were minimal with no comparable amount of data. 
Therefore they were eliminated from the study. Among the remaining cases, the first 60 
were included in the study. Of the 60 cases, 18 cases involved buccal mucosa, 17 cases 
involved alveolar mucosa, 14 cases involved retromolar zone, and 13 cases involved 
tongue. 7 cases were moderately differentiated OSCC and the remaining 53 cases were 
well differentiated OSCC. There were no poorly differentiated cases. All the patients had 
a positive habit history for atleast one of the following: Gutkha/maawa chewing, betal 
quid chewing, smoking, and snuff dipping. Patients who had multiple habits and 
alcoholism were eliminated. Some of the tongue OSCC cases had a history of trauma and 
they were also included in the study. The patients‟ age ranged from 26 to 86 years with 
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peak incidence in the 45 to 65 years. 65% of the patients were males and 35% were 
females. 
Among the 60 cases 7 of them were moderately differentiated OSCCs.  These two 
classes were separately considered in further evaluation, as the histological differentiation 
is already known to influence the bcl2/bax ratio and it can be a confounding factor.  
The bcl2/bax ratio for the cases were analysed in relation to age, sex, site, for any 
statistical significance. four subsites i.e; buccal mucosa, alveolar mucosa, retromolar zone 
and tongue were analysed for statistical significance for. Except for the site of the lesion 
other factors did not have any statistically significant influence on bcl2/bax. The bcl2/bax 
for the tongue was significantly higher than the other sites. Therefore the cases were 
divided into four groups according to the site. Within the groups, the bcl2/bax was 
assessed according to age groups (25-45 years, 46-65 years, 66-86 years), sex, habit and 
clinical stages (TNM Stage I, II, III and IV). Among the tongue cases, the ratio varied 
significantly between the sub-groups according to the habit/etiological factor. Tongue 
cases who had history of trauma had significantly higher value for bcl2/bax, than the 
other habits. 
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CONCLUSION: 
 This study shows that the ratio of principal anti- and pro- apoptotic regulators i.e, 
bcl2 and bax in OSCC is significantly high for tongue cases than the other subsites of oral 
cavity. And within the tongue cases, those that had history of trauma had higher values 
than the tongue cases with other etiological factors. As bcl2/bax is already known to be 
inversely proportional to prognosis, this study proves that the bcl2/bax ratio may be a 
factor for the poor prognosis of tongue OSCC cases. Further studies are required to study 
the relationship between trauma and bcl2/bax ratio. 
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APPENDIX - 1 
INFORMATION SHEET 
 
We are conducting a study on “CLINICOPATHOLOGIC EVALUATION OF PRO- 
AND ANTIAPOPTOTIC MARKER EXPRESSION IN ORAL SQUAMOUS CELL 
CARCINOMA.”  For that study, we are selecting patients. 
 The purpose of this study is to compare the cell proliferative index and to 
evaluate the role of causative factors among different sub sites within the 
oral cavity. 
 The identity of the patients participating in the research will be kept 
confidential throughout the study. In the event of any publication or 
presentation resulting from the research, no personally identifiable 
information will be shared. 
 Taking part in the study is voluntary. You are free to decide whether to 
participate in the study or to withdraw at any time; your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
 The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may 
aid in the management or treatment. 
 
 
 
Name of the patient               Signature / Thumb impression  
 
 
 
 
Name of the investigator   Signature   Date 
 
 
 
  
 
 
 
 
 
 
 
INFORMED CONSENT FORM 
 
 
STUDY TITLE: 
 
Clinicopathologic Evaluation of Pro- and Anti-apoptotic Marker  
Expression in Oral Squamous Cell Carcinoma 
  
 
Name      :           O.P.No: 
 
Age / Sex:                     H.P. No:                 
     
Address  :                S.No: 
 
Tel No    :           
      
 
I, _____________________________________________________ age ________ years 
exercising my free power of choice, hereby give my consent to be included as a 
participant in the study, ‘’Clinicopathologic Evaluation of Pro- and Anti-apoptotic 
Marker Expression in Oral Squamous Cell Carcinoma’’ 
 
I agree to the following: 
  
 I have been informed to my satisfaction about the purpose of the study and study 
procedures. 
 I hereby give permission to use my medical records for research purpose. I am 
told that the investigating doctor and institution will keep my identity 
confidential. 
 I agree to share my history of tobacco chewing/smoking habit, and was informed 
that the institution will keep it confidential. 
 I agree for the clinical examination done in this study. 
 I am aware that the tissue specimen used in this study is only that which was 
taken for biopsy and no extra tissue is taken for the study. 
 
 
 
 
         Name of the patient                   Signature / Thumb impression  
 
 
 
 
      Name of the investigator   Signature       Date 
APPENDIX - 4 
TABLE 1: MASTER CHART 
 
S. 
No. 
 
OP 
No. 
 
Age 
 
Site 
 
Gender 
 
Habit 
 
Clinical 
stage 
 
Differentiation 
 
Bcl2 
Sore 
 
Bax Score 
 
Bcl2/Bax 
ratio 
1 14150 70 BM F B Quid IV Well 3 10 0.3 
2 14151 26 T M Gutkha/Maawa II Well 6 11 0.54 
3 14248 30 BM M Gutkha/Maawa IV Mod 3 9 0.33 
4 14250 29 BM M Gutkha/Maawa I Well 5 9 0.55 
5 14257 27 BM M Gutkha/Maawa II Well 2 9 0.22 
6 14265 50 T M Gutkha/Maawa III Well 6 11 0.54 
7 14270 83 T M Trauma I Well 5 5 1 
8 14280 49 RMZ M Gutkha/Maawa IV Mod 6 5 1.2 
9 14284 41 BM M Gutkha/Maawa IV Well 2 5 0.4 
10 14288 41 RMZ M Gutkha/Maawa IV Well 4 8 0.5 
11 14300 55 AM F B. Quid IV Well 2 11 0.18 
12 14302 37 BM M Gutkha/Maawa I Well 2 5 0.4 
13 14312 65 BM F B Quid IV Well 2 4 0.5 
14 14318 50 BM F B Quid IV Mod 4 7 0.57 
15 14327 55 BM F B Quid III Well 3 10 0.3 
16 14328 79 RMZ M Gutkha/Maawa III Mod 10 7 1.42 
17 14329 86 AM M B Quid IV Well 3 6 0.5 
18 14347 35 T M Trauma III Well 4 3 1.33 
19 14350 58 BM F B Quid II Well 3 10 0.3 
20 14359 54 T M Gutkha/Maawa III Well 5 8 0.62 
21 14371 52 AM F B. Quid III Well 5 10 0.5 
22 14375 60 RMZ F B Quid  IV Well 2 4 0.5 
23 14383 47 AM M Smoking IV Well 3 5 0.6 
24 14384 45 AM F Gutkha/Maawa IV Mod 4 7 0.57 
25 14386 33 T M Trauma III Well 3 2 1.5 
26 14387 70 AM F Snuff IV Well 2 6 0.33 
27 14395 39 RMZ M Gutkha/Maawa IV Well 5 10 0.5 
28 14396 56 RMZ M Snuff IV Well 1 2 0.5 
29 14398 67 T M Smoking III Well 5 6 0.83 
30 14399 60 BM M Gutkha/Maawa IV Well 7 11 0.63 
31 14407 62 AM M Smoking III Well 3 8 0.37 
32 14410 55 T M Smoking IV Mod 3 2 1.5 
33 14411 55 BM F Snuff IV Well 2 6 0.33 
34 14415 60 RMZ M B Quid IV Well 4 5 0.8 
35 14419 48 BM F Snuff III Well 5 8 0.62 
36 14421 54 T M Gutkha/Maawa III Well 1 2 0.5 
37 14439 50 AM F B. Quid IV Well 5 8 0.62 
38 14440 65 AM M Smoking IV Well 2 5 0.4 
39 14441 58 RMZ M Smoking III Well 5 6 0.83 
40 14444 59 AM M B. Quid IV Well 2 9 0.22 
41 14446 52 RMZ M Smoking IV Well 2 4 0.5 
42 14449 35 T M Gutkha/Maawa III Well 7 10 0.7 
43 14458 75 AM M B. Quid IV Well 4 6 0.66 
44 14460 48 RMZ M Gutkha/Maawa IV Well 4 8 0.5 
45 14461 44 RMZ M Gutkha/Maawa III Well 4 6 0.66 
46 14468 32 T F Trauma III Well 7 7 1 
47 14472 75 AM F B. Quid I Well 4 6 0.66 
48 14473 53 BM F B Quid IV Well 4 11 0.36 
49 14477 62 T M Gutkha/Maawa IV Mod 3 4 0.75 
50 14480 47 AM F Snuff IV Well 1 2 0.5 
51 14497 38 RMZ M B Quid IV Well 1 1 1 
52 14501 55 BM F B Quid III Well 4 8 0.5 
53 14504 41 RMZ M Gutkha/Maawa I Well 4 12 0.33 
54 14507 51 AM F B. Quid IV Well 3 6 0.5 
55 14509 60 BM F Snuff dip IV Well 4 5 0.8 
56 14521 70 T M Trauma II Well 6 5 1.3 
57 14551 45 BM M smoking III Well 4 8 0.5 
58 14556 38 BM F Gutkha/Maawa IV Well 5 10 0.5 
59 14559 53 AM M Smoking III Well 2 3 0.66 
60 14597 60 AM M Smoking IV Well 5 10 0.5 
 
BM- Buccal mucosa, AM- Alveolar mucosa, RMZ- Retro molar zone, T- Tongue, M- Male, F- female, Well- Well differentiated OSCC, 
Mod- Moderately differentiated OSCC. 
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APPENDIX: VI 
COMMENTS & SUGGESTIONS OF SUPERVISOR 
Dr. Prathana 
  
I have received the files concerning your dissertation on 22-12-2012 through Dr. Baskar 
(Orthodontics PG). I have gone through it. My comments and suggestions are included 
below in a tabular format. Contact me as soon as you complete the changes.  
 
Comment 
1 
1.      Principal should be acknowledged 
first, followed by dissertation screening 
committee and ethical committee, and then 
proceed with acknowledging the rest. 
2.      Remove the word „guide‟ where ever 
necessary and replace with just „supervisor‟ 
3.     I thank Dr. I. Ponniah for his help in the 
dissertation and overall guidance during my 
MDS course. 
4.      I am not the principal investigator. 
5.      In the declaration by the student, state 
firmly that I (Dr. Prathana) is entirely 
responsible for any ethical violations (if any) 
and it does not have any binding on my 
supervisor. 
 
 
 
 
 
Corrections were made as 
suggested. 
 
 
     
Comment 
2a 
In the abstract section, include aim and 
objective(s). 
Aims & objective included in 
abstract section 
Comment 
2b 
“Or in other words, all neoplastic evolution 
requires two important steps, uncontrolled 
proliferation of cells and suppressed cell 
death of those cells. The later occurs by a 
process called apoptosis.
5”…………..verify 
The sentence was verified, 
and the error was identified. 
Changes made - The cell 
death occurs by a 
programmed process called 
69 
 
the underlined sentence.  apoptosis. 
Comment 
3a 
I am afraid whether the review of literature 
section is the same as one shown on 15-12-
2012? If it is a modified one then show to 
Dr. Jaikailash and ask him whether it can be 
written in the present format. 
Verified with Dr.Kailash, and 
the present  format was 
approved. 
Comment 
3b 
“The premise of your dissertation was to 
evaluate the immunohistochemical 
expression of bcl-2 and bax in conjunction 
with clinicopathological parameters to assess 
their significance in oral SCC.” Careful 
reading of the review of literature section, 
however, revealed that it does not pertain to 
the context in question. The aim of a 
literature review is to demonstrate that 
thorough knowledge pertinent to a given 
topic or question is gained or refined by 
reading the previous literature through 
critical analysis to explore the gaps or leads 
in the existing literature, and to relate your 
study with the previous literature to justify 
your research intentions. Therefore, the 
review of literature should be in context with 
the research objective(s) and also must 
establish that the literature lacks a similar 
study or must mention how this study differs 
with the previous study, if any. I would say 
that your existing literature search is 
inadequate and biased. Hence, kindly search 
relevant literature through electronic and 
hand search methods, and incorporate 
appropriately. 
The entire format of literature 
review was changed and and 
necessary corrections were 
made. 
Comment 
4 
The scientific content of the review of 
literature section should be convincing and 
comprehensible even to a non-pathology 
dental specialist. It should be written after 
reading relevant textual content than to write 
by truncating the abstract section of the 
The literature review is re-
written in a more descriptive 
way following the examples 
given by the supervisor. 
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source article. Adopt the following writing 
method in your literature review section. 
  
1.      Jordan et al (2005) studied the 
expression pattern of bcl-2 and bax in 30 
SCC and observed moderate to intense 
immunostaining in 60% and 63% of cases 
for bcl-2 and bax respectively. In this study, 
the pattern of expression of bcl-2 and bax 
was inversely related to the grade of the 
tumor with intense immunostaining for bcl-2 
and bax in poorly differentiated and well-
differentiated SCC respectively. The authors 
believed, based on the expression patterns, 
that alteration in bcl-2 and bax is likely to 
play a role in the development of SCC, 
especially during the early stages of 
epithelial carcinogenesis. 
  
2.      Lorro et al (2005) investigated bcl-2 
and bax by immunohistochemistry and in 
situ hybridization to correlate the expression 
pattern and to ascertain the mutational 
spectrum of these genes in epithelial 
dysplasia and oral SCC. They found that the 
expression of bax was widely noted in tumor 
cells of well-differentiated but not in poorly 
differentiated SCC compared to the low 
level of expression of bcl-2 in both 
histological grades of SCC. The authors 
concluded that loss of bcl-2 in basal cells of 
epithelial dysplasia and SCC as well as loss 
of bax in poorly differentiated SCC are not 
associated with mutations in the coding 
regions of these genes. 
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3.      Incorporate whenever possible the 
relative expression of markers within the 
stratum of the lesional epithelium. For 
example – see below. 
  
Lorro LL et al (1999) assessed expression 
of bcl-2 and bax in conjunction with 
histological grading in oral SCC. They 
observed a cytoplasmic staining pattern for 
bcl-2 within the thickness of normal 
epithelium with intense staining in the basal 
compartment, but negligible or loss of 
expression in the basal compartment of well-
differentiated SCC. In contrast, bax 
expression was more intense in the central 
than in the basal part of the epithelium with 
higher proportion of bax positive cells in 
well- and moderately differentiated SCC 
compared to poorly differentiated SCC. 
These indicate expression of bcl-2 and bax 
correlates with the histological grading in 
SCC. 
     
Comment 
5 
The listed studies warrant inclusion in the 
review of literature section. 
 
  Staibano S et al. Overexpression of cyclin-
D1, bcl-2, and bax proteins, proliferating cell 
nuclear antigen (PCNA), and DNA-ploidy in 
squamous cell carcinoma of the oral cavity. 
Hum Pathol 1998;29:1189-94. 
Included 
  Ito T et al. Decreased expression of Bax is 
correlated with poor prognosis in oral and 
oropharyngeal carcinoma. Cancer 
Lett 1999;140:81-91. 
Included 
  Homma A et al.  Prognostic significance of 
clinical parameters and biological markers in 
Included 
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patients with SCC of the head and neck 
treated with concurrent chemoradiotherapy. 
Clin Cancer Res 1999;5:801-806. 
  Lorro LL et al. Apoptosis and expression 
of Bax and Bcl-2 in snuff and non-snuff 
associated oral squamous cell carcinomas. 
Anticancer Res 2000;20:2855-60. 
This article was not available 
and then on permission from 
supervisor, it was included in 
the literature review written 
with the help of the abstract. 
  Teni T et al. Expression of bcl-2 and bax in 
chewing tobacco-induced oral cancers and 
oral lesions from India. Pathol Oncol 
Res 2002;8:109-114. 
Included 
  Saeed S et al. Immunohistochemical 
expression of Bax and Bcl-2 in penile 
carcinoma. Ann Clin Lab Sci 2005;35:91-96. 
Not included 
  Lorro LL et al. Loss of Bcl-2 in the 
progression of oral cancer is not attributable 
to mutations. J Clin Pathol 2005;58-1157-
1162. 
Included 
  Baltaziak M et al. Expression of Bcl-
xl, Bax, and p53 in primary tumors and 
lymph node metastases in oral squamous cell 
carcinoma. Ann NY Acad 
Sci 2006;1090:18-25. 
Included 
  de Vicente JC et al. Expression of Bcl-2 but 
not Bax has a prognostic significance in 
tongue carcinoma. J Oral Pathol 
Med 2006;35:140-145. 
Included  
  Jane C et al. Increased survivin expression 
in high-grade oral squamous cell carcinoma: 
a study in Indian tobacco chewers. J Oral 
Pathol Med 2006;35:595-601. 
Included  
  **Coutinho-Camillo CM et al. Expression 
of Bcl-2 family proteins and association with 
clinicopathological characteristics of oral 
This aricle was quoted in the 
indtroduction section and 
hence was mentioned in the 
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squamous cell carcinoma. 
Histopathology2010;57:304-16. 
  
Note: Although you have referenced this 
article in the bibliography section, it was not 
included in the review of literature section. 
  
bibliography section. Now it 
is also included in literature 
review section. 
  de Sousa FA et al. Comparative analysis of 
the expression of PCNA, p53, bax, and bcl-
2 in oral lichen planus and oral squamous 
cell carcinoma. Ann Diagn 
Pathol2009;13:308-312. 
Included 
  Ranganathan K et al. Proliferation and 
apoptosis markers in oral submucous 
fibrosis. J Oral Maxillofac 
Pathol 2011;15:148-153. 
Included 
  Zhao J et al. Analysis of 
thermochemotherapy-induced apoptosis and 
the protein expressions of bcl-2 and bax in 
maxillofacial squamous cell carcinoma. Med 
Oncol2011;28:S354-359. 
Included 
  Jham BC et al. Midkine expression in oral 
squamous cell carcinoma and leukoplakia. J 
Oral Pathol Med 2012;41:21-26. 
Included 
  Bose P et al. Bax expression measured by 
AQUA analysis is an independent prognostic 
marker in oral squamous cell carcinoma. 
BMC Cancer 2012;12:332. 
Included 
     
Comment 
6a 
I wish to know, as you have stated in your 
MM section, that who are those 2 or 3 
observers who reviewed the IHC slide for 
interpretations? 
Only one observer reviewed 
the slides. The corrections are 
made in the document.  
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Comment 
6b 
Annexures should be placed at the back of 
the document and not at the beginning of the 
R section. 
Adopted 
Comment 
7 
Certain information regarding patient 
grouping should be mentioned in the MM 
section and not in the R section. 
Adopted  
Comment 
8 
Check the bibliography section for 
uniformity. 
Checked for uniformity.  
 
With regards 
  
Irulandy Ponniah, MDS 
Professor and Head 
Department of Oral Pathology 
TN Government Dental College and Hospital 
Chennai 600 003. 
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APPENDIX - 7 
DISSERATION HISTORY & PRE-HISTORY 
   
 Whether a course in research methodology was 
attended? 
Yes, from 31.01.2011 to 
04.02.2011 
 Whether adequate training obtained before starting 
dissertation with regard to conception, design and 
literature search?  
Yes, it was given in the first 
year of MDS course. 
 When was the dissertation topic selected? 16.11.2011 
 Whether topic selection was discussed with the 
guide? 
Yes 
 Whether a research question put forth? Yes 
 Whether aim and objective was discussed and got 
approved from the guide? 
Yes, 02.12.2011 
 Whether materials and methods discussed and got 
approved? 
Yes, 02.12.2011 
 Whether the topic got approved from the dissertation 
screening and ethical committees? 
Yes, 25.01.2012 
 Whether the study protocol differed from that 
initially conceived and approved by the ethical 
committee? If yes, state the reasons. 
Yes, for analysis of IHC 
stained tissues manual 
method is now followed 
instead of image analysis 
software as it was not 
accurate. 
 Whether the data for review of literature discussed 
with the guide? 
No. 
 Whether literature review was shown to the guide, 
and if yes, when it was shown? 
Yes (15.12.2012) 
 Who did data analysis and interpretation? Myself  
 Who did statistical analysis and when it was 
completed? 
Statistician (18.12.2012) 
 Whether bibliography discussed with the guide? No. 
 Whether printed copy of bibliographies provided to 
the guide? 
Yes. 
 When was the following textual content shown to the guide? When was returned to 
you after correction? Whether the following were approved on initial submission or 
required number of corrections? 
 
 Submitted date Approved Date 
Introduction 18.08.2012 23.08.2012 
Aims & Objective 02.12.2011 02.12.2011 
Review of literature 15.12.2012 & 22.12.2012 24.12.2012 
Materials & Methods 02.12.2011 02.12.2011 
Results 22.12.2012 24.12.2012 
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Discussion 22.12.2012 24.12.2012 
Conclusion 22.12.2012 24.12.2012 
Bibliography 15.12.2012 & 22.12.2012 24.12.2012 
 Whether the above sections were edited for language 
and intellectual content? 
 
Whether the final document was checked for overlap 
with previous work by others? 
Yes 
 
 
Checked only for 
Introduction. 
 Whether answer was found to the research question? Yes 
   
 
